Novel agents for the treatment of childhood acute leukemia

Colleen E. Annesley, Patrick A Brown

Research output: Contribution to journalReview article

Abstract

Together, acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) make up approximately one-third of all pediatric cancer diagnoses. Despite remarkable improvement in the treatment outcomes of these diseases over the past several decades, the prognosis for certain high-risk groups of leukemia and for relapsed disease remains poor. However, recent insights into different types of driver' lesions of leukemogenesis, such as the aberrant activation of signaling pathways and various epigenetic modifications, have led to the discovery of novel agents that specifically target the mechanism of transformation. In parallel, emerging approaches in cancer immunotherapy have led to newer therapies that can exploit and harness cytotoxic immunity directed against malignant cells. This review details the rationale and implementation of recent and specifically targeted therapies in acute pediatric leukemia. Topics covered include the inhibition of critical cell signaling pathways [BCR-ABL, FMS-like tyrosine kinase 3 (FLT3), mammalian target of rapamycin (mTOR), and Janus-associated kinase (JAK)], proteasome inhibition, inhibition of epigenetic regulators of gene expression [DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, and disruptor of telomeric signaling-1 (DOT1L) inhibitors], monoclonal antibodies and immunoconjugated toxins, bispecific T-cell engaging (BiTE) antibodies, and chimeric antigen receptor-modified (CAR) T cells.

Original languageEnglish (US)
Pages (from-to)61-79
Number of pages19
JournalTherapeutic Advances in Hematology
Volume6
Issue number2
DOIs
StatePublished - 2015

    Fingerprint

Keywords

  • ALL
  • AML
  • blinatumomab
  • CAR T-cells
  • carfilzomib
  • EPZ-5676
  • FLT3
  • moxetumomab

ASJC Scopus subject areas

  • Hematology

Cite this